Drug Profile
Norethisterone acetate transdermal - Pierre Fabre
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Amarin Corporation
- Class Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 01 Apr 2008 Discontinued - Preregistration for Menopausal syndrome in France (Transdermal)
- 17 Jun 2003 No development reported - Preregistration for Menopausal syndrome in France (Transdermal)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance